Advanced glycosylation end product-specific receptor · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Advanced glycosylation end product-specific receptor shows late clinical disease relevance led by Alzheimer disease. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q15109. Start with Alzheimer disease, then reuse UniProt Q15109 as the stable protein anchor across project notes and exports.
Start with Alzheimer disease, then reuse UniProt Q15109 as the stable protein anchor across project notes and exports.
Advanced glycosylation end product-specific receptor shows late clinical disease relevance led by Alzheimer disease. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Alzheimer disease because it currently carries late clinical support. Linked drugs include AZELIRAGON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyAdvanced glycosylation end product-specific receptor
Review this target as Advanced glycosylation end product-specific receptor, mapped to UniProt Q15109. Sequence length is 404 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Advanced glycosylation end product-specific receptor as ChEMBL target CHEMBL2176846, mapped to UniProt Q15109. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Advanced glycosylation end product-specific receptor is the right protein anchor across sources, using UniProt Q15109 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Alzheimer disease is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Advanced glycosylation end product-specific receptor |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q15109 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Advanced glycosylation end product-specific receptor |
| UniProt Accession | Q15109 |
| Component Type | Protein |
| Sequence Length | 404 aa |
Advanced glycosylation end product-specific receptor
Review this target as Advanced glycosylation end product-specific receptor, mapped to UniProt Q15109. Sequence length is 404 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Advanced glycosylation end product-specific receptor shows late clinical disease relevance led by Alzheimer disease. 3 more disease programs remain visible in the same review block.
Start review with Alzheimer disease because it currently carries late clinical support. Linked drugs include AZELIRAGON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4101927 | 10.0 | Kd | 0.1 | Preclinical |
| CHEMBL1335502 | 9.26 | Kd | 0.55 | Preclinical |
| CHEMBL5176926 | 9.0 | Kd | 1.0 | Preclinical |
| CHEMBL4077165 | 9.0 | Kd | 1.0 | Preclinical |
| CHEMBL1477694 | 9.0 | Kd | 1.0 | Preclinical |
| CHEMBL1342645 | 8.92 | Kd | 1.2 | Preclinical |
| CHEMBL6043937 | 8.85 | Kd | 1.4 | Preclinical |
| CHEMBL5815349 | 8.7 | Kd | 2.0 | Preclinical |
| CHEMBL4072531 | 8.7 | Kd | 2.0 | Preclinical |
| CHEMBL4063929 | 8.7 | Kd | 2.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 21 | 54 | 6.3 |
| assay format | 6 | 32 | 6.8 |
| cell-based format | 5 | 2 | 7.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 1 | 0 | — |